Alcoholic Hepatitis: A Clinician's Guide

Clinics in Liver Disease

Volumn 16, Issue 2, 2012, Pages 371-385

  Choi, Gina ^a   Runyon, Bruce Allen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Santa Monica UCLA Medical Center   (United States)

Author keywords

Alcoholic liver disease; Corticosteroids; Discriminant function; Pentoxifylline

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BACLOFEN; CHLORDIAZEPOXIDE; ETANERCEPT; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID; INFLIXIMAB; LORAZEPAM; MIDODRINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OCTREOTIDE; OXANDROLONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; SPIRONOLACTONE; TECHNETIUM SULFUR COLLOID TC 99M; TERLIPRESSIN; VITAMIN K GROUP;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CULTURE; BODY MASS; BODY WEIGHT; CLINICAL FEATURE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CUSHING SYNDROME; DIET SUPPLEMENTATION; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERIC FEEDING; FEVER; FLUID RETENTION; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLASGOW ALCOHOLIC HEPATITIS SCORE; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATOMEGALY; HEPATORENAL SYNDROME; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INTERVIEW; IRON OVERLOAD; JAUNDICE; LEUKOCYTOSIS; LILLE MODEL; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MADDREY DISCRIMINANT FUNCTION; MODEL FOR END STAGE LIVER DISEASE; MORTALITY; OBESITY; PARACENTESIS; PHYSICAL EXAMINATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIDIVISM; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SCORING SYSTEM; SHORT TERM SURVIVAL; THORAX RADIOGRAPHY; WAIST CIRCUMFERENCE;

ADRENAL CORTEX HORMONES; ANABOLIC AGENTS; BACLOFEN; DIETARY SUPPLEMENTS; GABA-B RECEPTOR AGONISTS; HEPATITIS, ALCOHOLIC; HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; OXANDROLONE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860299445     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.03.015     Document Type: Review

References (71)

1. O'Shea R., Kinnard M.F., Umar N., et al. Treatment of alcoholic hepatitis (AH) in clinical practice. Gastroenterology 2009, 136(5):A830-A831.
2. Beckett A.G., Livingstone A.V., Hill K.R. Acute alcoholic hepatitis. Br Med J 1961, 2(5260):1113-1119.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington, DC: Author; 2000.
4. Kim W.R., Brown R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36(1):227-242.
5. Rehm J., Mathers C., Popova S., et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009, 373(9682):2223-2233.
6. Yoon Y. Surveillance report #88 liver cirrhosis mortality in the United States 1970-2007. Available at: . Accessed November 20, 2011. http://pubs.niaaa.nih.gov/publications/surveillance88/Cirr07.htm.
7. Asrani S.K., Kamath P.S., Pedersen R., et al. Liver related mortality in the US is underestimated. Hepatology 2010, 52(4):408A.
8. Becker U., Deis A., Sørensen T.I., et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996, 23(5):1025-1029.
9. Mandayam S., Jamal M.M., Morgan T.R. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004, 24(3):217-232.
10. Bellentani S., Saccoccio G., Costa G., et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997, 41(6):845-850.
11. Asrani S.K., Larson J.J., Benson J.T., et al. Survival of patients with alcoholic hepatitis: a population-based study. Hepatology 2010, 52(4):1111-1112.
12. Frezza M., di Padova C., Pozzato G., et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990, 322(2):95-99.
13. Gutierrez-Reyes G., Rosique D., Corona-Caloca L.E., et al. Association of genetic polymorphisms of ADH1B, ALDH2 and CYP2E1 with alcoholism in a group of mexican mestizos. Hepatology 2011, 54:522A.
14. Yoon Y.H., Yi H.Y., Thomson P.C. Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res 2011, 35(2):240-249.
15. Singal A.K. Comments on AASLD practice guidelines for alcoholic liver disease. Hepatology 2010, 51(5):1860-1861. [author reply: 1861].
16. Levitsky J., Mailliard M.E. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004, 24(3):233-247.
17. Sass D.A., Shaikh O.S. Alcoholic hepatitis. Clin Liver Dis 2006, 10(2):219-237. vii.
18. Lischner M.W., Alexander J.F., Galambos J.T. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis 1971, 16(6):481-494.
19. Morales A.M., Hashimoto L.A., Mokhtee D. Alcoholic hepatitis with leukemoid reaction after surgery. J Gastrointest Surg 2006, 10(1):83-85.
20. Mitchell R.G., Michael M., Sandidge D. High mortality among patients with the leukemoid reaction and alcoholic hepatitis. South Med J 1991, 84(2):281-282.
21. Juturi J.V., Hopkins T., Farhangi M. Severe leukocytosis with neutrophilia (leukemoid reaction) in alcoholic steatohepatitis. Am J Gastroenterol 1998, 93(6):1013.
22. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119(6):1637-1648.
23. Uchida T., Kao H., Quispe-Sjogren M., et al. Alcoholic foamy degeneration-a pattern of acute alcoholic injury of the liver. Gastroenterology 1983, 84(4):683-692.
24. O'Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Am J Gastroenterol 2010, 105(1):14-32. [quiz: 33].
25. Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94(4):1018-1022.
26. Delanghe J., De Buyzere M.L. Carbohydrate deficient transferrin and forensic medicine. Clin Chim Acta 2009, 406(1-2):1-7.
27. Poynard T., Zourabichvili O., Hilpert G., et al. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984, 4(2):324-327.
28. Milman N., Graudal N. Serum ferritin in acute viral hepatitis. Scand J Gastroenterol 1984, 19(1):38-40.
29. Hoefs J.C., Green G., Reynolds T.B., et al. Mechanism for the abnormal liver scan in acute alcoholic liver injury. Am J Gastroenterol 1984, 79(12):950-958.
30. Hoefs J.C., Wang F., Kanel G. Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. Am J Gastroenterol 1997, 92(11):2054-2058.
31. Everson G.T., Shiffman M.L., Hoefs J.C., et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the HALT-C trial. Hepatology 2011 Oct 26, [Epub ahead of print]. DOI: 10.1002/hep.24752.
32. Lefkowitch J.H. Morphology of alcoholic liver disease. Clin Liver Dis 2005, 9(1):37-53.
33. Jensen K., Gluud C. The mallory body: morphological, clinical and experimental studies (part 1 of a literature survey). Hepatology 1994, 20(4 Pt 1):1061-1077.
34. Maddrey W.C., Boitnott J.K., Bedine M.S., et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75(2):193-199.
35. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41(2):353-358.
36. Forrest E.H., Evans C.D., Stewart S., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54(8):1174-1179.
37. Srikureja W., Kyulo N.L., Runyon B.A., et al. MELD score is a better prognostic model than child-turcotte-pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005, 42(5):700-706.
38. Forrest E.H., Morris A.J., Stewart S., et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007, 56(12):1743-1746.
39. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45(6):1348-1354.
40. Sandahl T.D., Jepsen P., Ott P., et al. Validation of prognostic scores for clinical use in patients with alcoholic hepatitis. Scand J Gastroenterol 2011, 46(9):1127-1132.
41. Mendenhall C.L., Anderson S., Weesner R.E., et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984, 76(2):211-222.
42. Cabré E., Rodríguez-Iglesias P., Caballería J., et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000, 32(1):36-42.
43. Applied Medical Technology Inc. AMT Bridle Nasal Tube Retaining System. Available at: . http://www.appliedmedical.net.
44. Ramond M.J., Poynard T., Rueff B., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326(8):507-512.
45. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. N Engl J Med 2009, 360(26):2758-2769.
46. Christensen E., Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995, 37(1):113-118.
47. Rambaldi A., Saconato H.H., Christensen E., et al. Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008, 27(12):1167-1178.
48. Mathurin P., O'Grady J., Carithers R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011, 60(2):255-260.
49. Amini M., Runyon B.A. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010, 16(39):4905-4912.
50. McHutchison J.G., Runyon B.A., Draguesku J.O., et al. Pentoxifylline may prevent renal impairment (hepatorenal-syndrome) in severe acute alcoholic hepatitis. Hepatology 1991, 14(4):A96.
51. De B.K., Gangopadhyay S., Dutta D., et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15(13):1613-1619.
52. Nguyen-Khac E., Thevenot T., Piquet M.A., et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011, 365(19):1781-1789.
53. Louvet A., Diaz E., Dharancy S., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008, 48(3):465-470.
54. Naveau S., Chollet-Martin S., Dharancy S., et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004, 39(5):1390-1397.
55. Boetticher N.C., Peine C.J., Kwo P., et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008, 135(6):1953-1960.
56. Schwabe R.F., Brenner D.A. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006, 290(4):G583-G589.
57. Mendenhall C.L., Anderson S., Garcia-Pont P., et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984, 311(23):1464-1470.
58. Orr R., Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 2004, 64(7):725-750.
59. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370(9603):1915-1922.
60. Garbutt J.C., Kampov-Polevoy A.B., Gallop R., et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010, 34(11):1849-1857.
61. Addolorato G., Leggio L., Ferrulli A., et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011, 46(3):312-317.
62. Enserink M. Addiction research. Anonymous alcoholic bankrolls trial of controversial therapy. Science 2011, 332(6030):653.
63. Watt K., Uhanova J., Minuk G.Y. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002, 97(8):2046-2050.
64. Fagundes C., Pepin M.N., Guevara M., et al. Evaluation of four different urinary biomarkers in the assessment of renal failure in cirrhosis. Role for urinary neutrophil gelatinase-associated lipocalin. Hepatology 2011, 54:1234A.
65. Cavallin M., Fasolato S., Sticca A., et al. Increased urinary level of neutrophil gelatinase-associated lipocalin (NGAL) In patients with cirrhosis and type 1 HRS. Hepatology 2011, 54:1254A-1255A.
66. Esrailian E., Pantangco E.R., Kyulo N.L., et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007, 52(3):742-748.
67. Skagen C., Einstein M., Lucey M.R., et al. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009, 43(7):680-685.
68. Boyer T.D., Sanyal A.J., Garcia-Tsao G., et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 2011, 55(2):315-321.
69. Veldt B.J., Lainé F., Guillygomarc'h A., et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002, 36(1):93-98.
70. Mathurin P., Moreno C., Samuel D., et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011, 365(19):1790-1800.
71. Brown R.S. Transplantation for alcoholic hepatitis-time to rethink the 6-month " rule" . N Engl J Med 2011, 365(19):1836-1838.